The pharmaceutical company said its drug baricitinib, combined with remdesivir, reduces median hospital stays by one day compared to remdesivir alone, and is pursuing an emergency use authorization with the FDA.
Lilly’s Rheumatoid Arthritis Drug Shortens Covid-19 Hospitalization When Combined With Antiviral Med
